[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neoplasms-connective-and-soft-tissue\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neoplasms-connective-and-soft-tissue":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100261087","an-electronic-health-record-ehr-based-comprehensive-bone-and-soft-tissue-tumor-registry-100261087",false,"NCT02677961","An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry","Inclusion Criteria:\n\n* Must have a diagnosis or presumed diagnosis of bone or soft tissue tumor as defined by the WHO classification of tumors of soft tissue and bone (4th ed.)\n* Patient, or his\u002Fher designated power of attorney, must be able to understand and approve of the consent to participate.\n\nExclusion Criteria:\n\n* Prisoners are excluded from participation in the Registry.","ALL","18 Years",{"count":18,"type":19},1500,"ESTIMATED","5 Years","OBSERVATIONAL","Translational studies in cancer research can be impeded by the lack of high-quality clinical data that can be correlated with research questions. This is particularly true in the case of rare diseases, such as bone and soft tissue tumors. It is therefore the purpose of this study to create a prospective EHR-based clinical registry for individuals with bone and soft-tissue tumors.",[24,25],"Neoplasms, Connective and Soft Tissue","Bone Neoplasms",[27,28],"sarcoma","registry","RECRUITING","2026-02-09",{"date":32,"type":33},"2026-02-11","ACTUAL",{"date":35,"type":33},"2015-07-01",{"date":37,"type":19},"2027-12-31",{"name":39,"class":40},"Ohio State University Comprehensive Cancer Center","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":69,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":41},"100473080","phase-4-percutaneous-needle-fasciotomy---corticosteroid-injection-for-dupuytrens-contracture-100473080","NCT05440240","Percutaneous Needle Fasciotomy +\u002F- Corticosteroid Injection for Dupuytren's Contracture","Percutaneous Needle Fasciotomy (PNF) +\u002F- Corticosteroid Injection for Dupuytren's Contracture (DC) Affecting Metacarpophalangeal Joints (MCP) . A Randomized Controlled Trial","Sufficient correction of metacarpophalangeal (MCP) joint during the PNF treatment, defined as \\\u003C20° passive extension deficit (PED), is a prerequisite for inclusion.\n\nInclusion Criteria:\n\n* Dupuytren contracture (DC) of ≥ 20° PED in MCP joint measured with a goniometer\n* DC of either II-V finger\n* Well-defined\u002Fpalpable cord\n\nExclusion Criteria:\n\n* Legally incapacitated\n* Previous study inclusion with another finger ray\n* Isolated proximal interphalangeal (PIP) or distal interphalangeal (DIP) joint contracture, defined as MCP joint contracture \\\u003C 20° PED regardless of the deficit in the PIP or DIP joint\n* Previous hand surgery of the affected finger for any reason\n* Known allergy to the study medication\n* Anticoagulant therapy (Acetylsalicylic acid is NOT an exclusion criterion)\n* Pregnant or lactation\n* Insulin dependent diabetes mellitus\n* Ongoing systemic infection or local infection at the site of the procedure\n* Rheumatoid arthritis\n* Amyloidosis or mucopolysaccharidosis\n* Unable to communicate, cooperate or participate in follow-up","45 Years","99 Years",{"count":52,"type":19},400,"INTERVENTIONAL",[55],"PHASE4","Comparing percutaneous needle fasciotomy +\u002F- corticosteroid injection for Dupuytren's contracture affecting metacarpophalangeal joints. A clinician-initiated, multicenter, randomized controlled trial.",[58,59,60,61,62,63,64,65,24,66,67,68],"Dupuytren Contracture","Dupuytren's Disease","Contracture","Joint Diseases","Musculoskeletal Diseases","Fibroma","Neoplasm, Fibrous Tissue","Neoplasms, Connective Tissue","Neoplasms by Histologic Type","Neoplasms","Connective Tissue Diseases",[70,71,72],"Percutaneous needle fasciotomy","Corticosteroid","Randomized controlled trial","2023-05-15",{"date":75,"type":33},"2023-05-17",{"date":77,"type":33},"2023-01-10",{"date":79,"type":19},"2030-03",{"name":81,"class":40},"Regionshospitalet Silkeborg"]